Chengdu Olymvax Biopharmaceuticals (688319) Stock Overview

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sale of human vaccines. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and Staphylococcus aureus, which is in Phase 3 clinical trial. In addition, it engages in promotion and application service business. The company was founded in 2009 and is based in Chengdu, China.